Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702293 | 1.00 | CRBN (0.44) | CRBNLMNAPOLBGAAGHSR | |
| SCHEMBL1188908 | 1.00 | CRBN (0.44) | CRBNLMNAPOLBGAAGHSR | |
| SCHEMBL4326248 | 0.79 | IDO1 (0.40) | CRBNGAAGHSRTSHR | |
| SCHEMBL8827117 | 0.75 | KMT2A (0.34) | CRBNLMNAPOLBGAAMAPT | |
| SCHEMBL24391155 | 0.72 | MAPT (0.33) | LMNAPOLBGAAMAPT | |
| SCHEMBL25903191 | 0.72 | POLB (0.33) | LMNAPOLBGAA | |
| SCHEMBL24391153 | 0.72 | MAPT (0.33) | LMNAPOLBGAAMAPT | |
| SCHEMBL5196812 | 0.70 | BRD4 (0.57) | GAAGHSRMAPTTSHR | |
| SCHEMBL5191751 | 0.70 | BRD4 (0.57) | GAAGHSRMAPTTSHR | |
| SCHEMBL24180567 | 0.70 | GHSR (0.36) | CRBNGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0672036-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-09-20 | — | — | EP | claimed |
| WO-1994004513-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | claimed |
| CN-113906018-A | 1- ((S) -1- (3-chloro-5-fluoro-2- ((4- (1H-pyrazol-1-yl) -2-methylquinolin-8-yloxy) methyl) phenyl) ethyl) -imidazolidine-2, 4-dione derivatives and related compounds for Bradykinin (BK) B2 receptor antagonists for the treatment of skin diseases | 法瓦里斯有限责任公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3354655-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | University Of Southern California, USC Stevens (US) | 2018-08-01 | — | — | EP | disclosed |
| CN-104755084-B | Suppress the active composition and method and its purposes for treating tumour of hypoxia-inducible transcription factor complex | 南加州大学 | 2018-04-03 | — | — | CN | disclosed |
| EP-2890382-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | UNIV SOUTHERN CALIFORNIA (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3209664-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9416145-B2 | Compositions and methods for inhibiting activity of hypoxia-inducible transcription factor complex and its use for treatment of tumors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150246933-A1 | Compositions and Methods for Inhibiting Activity of Hypoxia-Inducible Transcription Factor Complex and Its Use for Treatment of Tumors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-09-03 | — | — | US | disclosed |
| CN-104755084-A | Compositions and methods for inhibiting activity of hypoxia-inducible transcription factor complex and its use for treatment of tumors | UNIV SOUTHERN CALIFORNIA | 2015-07-01 | — | — | CN | disclosed |
| EP-2157856-A1 | HERBICIDALLY EFFECTIVE COMPOSITION | Basf Se (DE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008152074-A1 | HERBICIDALLY EFFECTIVE COMPOSITION | BASF SE (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-1995021283-A1 | PROCESS FOR BLEACHING TEXTILES | WARWICK INTERNATIONAL GROUP LIMITED (GB) | 1995-08-10 | — | — | WO | disclosed |
| EP-0552360-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-07-28 | — | — | EP | disclosed |
| WO-1993003825-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |
| EP-0216744-A2 | The compound 1,4-diisopropyl-2,5-diketopiperazine | Monsanto Company (US) | 1987-04-01 | — | — | EP | disclosed |
| EP-0068866-A1 | Method of manufacturing acetone or methyl ethyl ketone | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246933-A1 | Compositions and Methods for Inhibiting Activity of Hypoxia-Inducible Transcription Factor Complex and Its Use for Treatment of Tumors | HIF1AN, HIF1A, EGLN2 | CRBN 755/4885LMNA 3269/4885POLB 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.